8-K: KORU Medical Secures $10 Million Credit Facility, Reports Mixed 2023 Results, and Issues 2024 Guidance

KORU Medical announced a new $10 million credit facility, alongside its fourth quarter and full year 2023 financial results, and provided revenue guidance for 2024.

Summary

• KORU Medical Systems reported a 2% decrease in fourth-quarter 2023 net revenues to $7.2 million compared to the prior year.
• Full-year 2023 net revenues reached $28.5 million, a 2% increase year-over-year.
• The company experienced 6.7% core business growth, driven by the SCIg market, share gains, and expansion into new geographies.
• Gross margin improved to 60.3% in the fourth quarter and 58.6% for the full year, reflecting a 470 and 350 basis point increase respectively.
• KORU Medical achieved positive cash flow of $0.7 million in the fourth quarter of 2023, ending the year with $11.5 million in cash.
• The company entered into three novel therapy collaborations in 2023 and announced two more in the first quarter of 2024.
• A non-cash valuation allowance against deferred tax assets of $6.0 million contributed to a net loss of $13.7 million, or $0.30 per share, for the year.
• Adjusted EBITDA for the year was ($6.0) million, or ($0.13) per share, compared to ($6.1) million, or ($0.14) per share in the prior year.
• KORU Medical secured a $10 million credit facility with HSBC USA, replacing an expired $3.5 million revolver agreement.
• The company issued full-year 2024 net revenue guidance of $31.2-$32.2 million, projecting 10-13% growth.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive growth in core business and improved margins, but also significant losses and risks related to EU certification. The new credit facility and positive cash flow in Q4 are encouraging, but the overall sentiment is cautiously optimistic.

Positives

• The company's core business is experiencing solid growth, driven by market expansion and share gains.
• Gross margins have improved significantly, indicating better operational efficiency.
• KORU Medical achieved positive cash flow in the fourth quarter of 2023.
• The new credit facility provides financial flexibility for strategic growth.
• The company is projecting strong revenue growth for 2024.
• KORU Medical is expecting to achieve cash flow breakeven in late 2024 and be cash flow positive in 2025.

Negatives

• Fourth-quarter 2023 net revenues decreased by 2% compared to the prior year.
• Novel Therapies net revenues declined by 62% in the fourth quarter and 41.6% for the full year due to the completion of a large milestone in 2022.
• The company recorded a significant non-cash valuation allowance against deferred tax assets of $6.0 million.
• The company reported a net loss of $13.7 million for the full year 2023.
• KORU Medical received an assessment report from BSI in the EU that could impact certification.

Risks

• The company's EU certification is under review, which could impact its European operations.
• The company faces risks associated with SCIg market growth, prefilled syringe penetration, and plasma supply.
• There are uncertainties related to clinical trial activity and success.
• The company is subject to risks related to customer ordering patterns, global health crises, and competition.
• KORU Medical is exposed to labor and supply price increases, inflationary impacts, and labor supply issues.

Future Outlook

KORU Medical expects full-year 2024 net revenue between $31.2 and $32.2 million, representing 10-13% growth, and anticipates achieving cash flow breakeven in the fourth quarter of 2024 and being cash flow positive for the full year 2025. The company also expects gross margin between 59% and 61% for the full year 2024 and a year-end cash balance greater than $8.0 million.

Management Comments

• Linda Tharby, KORU Medical's President and CEO, stated that she is proud of the team for delivering a solid end to 2023, led by performance in the core business.
• She highlighted the entry into multiple geographic markets driving international sales and the FDA clearance and launch of the 50mL prefill pump platform as key milestones.
• She also noted double-digit growth in end-user specialty pharmacy sales, reflecting share gains and a growing Ig market.
• She mentioned recent collaborations for two late-stage therapies within the Novel Therapies business.
• She emphasized the focus on executing the Vision 2026 strategy and positioning KORU for growth, profitability, and value creation.

Industry Context

This announcement reflects KORU Medical's efforts to capitalize on the growing subcutaneous immunoglobulin (SCIg) market and expand its presence in new geographic regions. The company's focus on novel therapies and strategic collaborations aligns with industry trends towards personalized medicine and innovative drug delivery systems. The new credit facility is a strategic move to support growth initiatives and compete effectively in the medical technology sector.

Comparison to Industry Standards

• KORU Medical's 2% revenue growth for 2023 is modest compared to some high-growth medical technology companies, but the 6.7% core business growth is a positive sign.
• The improvement in gross margin to 58.6% is a positive trend, but it is important to compare this to peers like ICU Medical or Baxter International, which have similar product lines.
• The company's adjusted EBITDA of ($6.0) million indicates ongoing challenges with profitability, which is a common issue for growth-stage medical device companies.
• The $10 million credit facility is a typical financing strategy for companies in this sector, similar to what companies like Insulet or Tandem Diabetes Care have used to fund expansion.
• The 10-13% revenue growth guidance for 2024 is a positive outlook, but it will be important to see if the company can achieve this in the face of market competition and supply chain challenges.

Stakeholder Impact

• Shareholders may be cautiously optimistic due to the revenue growth guidance and improved margins, but concerned about the net losses and EU certification risks.
• Employees may be encouraged by the company's growth prospects and new strategic initiatives.
• Customers may benefit from the company's focus on innovative and patient-centric solutions.
• Suppliers may see increased business opportunities as the company expands its operations.
• Creditors may be reassured by the new credit facility and the company's focus on achieving cash flow breakeven.

Next Steps

• The company will focus on executing its Vision 2026 strategy.
• KORU Medical will continue to expand into new geographic markets.
• The company will work to penetrate the prefilled syringe market.
• KORU Medical will focus on achieving cash flow breakeven in late 2024 and be cash flow positive in 2025.
• The company will appeal the BSI assessment report in the EU.

Key Dates

Keywords

KORU Medical, subcutaneous infusion, medical technology, credit facility, financial results, revenue guidance, gross margin, EBITDA, SCIg, novel therapies